Related Experiment Videos
Dexmedetomidine and neurocognitive testing in awake craniotomy
Patricia Fogarty Mack1, Kenneth Perrine, Erik Kobylarz
1Weill Medical College of Cornell University, New York, New York 10021, USA. pmack@med.cornell.edu
Journal of Neurosurgical Anesthesiology
|December 17, 2003
Summary
Dexmedetomidine, a sedative, shows promise for awake craniotomy. This alpha-2 adrenoreceptor agonist offers sedation and analgesia without respiratory depression, making it suitable for neurocognitive testing during brain surgery.
Area of Science:
- Neurosurgery
- Anesthesiology
- Pharmacology
Background:
- Awake craniotomy requires patient cooperation for neurocognitive testing in eloquent brain areas.
- Current anesthetic techniques carry risks, including respiratory depression.
- Dexmedetomidine, a selective alpha-2 adrenoreceptor agonist, was investigated for its sedative and analgesic properties without respiratory compromise.
Observation:
- A case series of 10 patients undergoing awake craniotomy using dexmedetomidine infusion was reviewed.
- Patients received either an "asleep-awake" technique or moderate sedation.
- Dexmedetomidine was administered as a loading dose followed by continuous infusion.
Findings:
- No permanent neurological deficits were observed.
- One patient experienced a temporary worsening of preoperative language difficulties.
- Dexmedetomidine facilitated successful sensory, motor, and neurocognitive testing.
Implications:
- Dexmedetomidine is a potentially valuable sedative for awake craniotomy.
- Its use may be particularly beneficial when detailed neurologic assessments are necessary.
- Further research can explore optimal dexmedetomidine dosing for various awake craniotomy scenarios.